Sildenafil for chronic obstructive pulmonary disease: A randomized crossover trial

David J. Lederer, Matthew N. Bartels, Neil W. Schluger, Frances Brogan, Patricia Jellen, Byron M. Thomashow, Steven M. Kawut

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95 confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life.

Original languageEnglish (US)
Pages (from-to)268-275
Number of pages8
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume9
Issue number3
DOIs
Publication statusPublished - Jun 1 2012
Externally publishedYes

    Fingerprint

Keywords

  • COPD
  • Clinical Trial
  • Emphysema
  • Pulmonary hypertension.
  • Sildenafil

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this